211 related articles for article (PubMed ID: 29367471)
1. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
[TBL] [Abstract][Full Text] [Related]
2. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
[TBL] [Abstract][Full Text] [Related]
3. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Goto H; Mita T; Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Nishimura H; Kuroda H; Matsubara T; Gosho M; Ishii H; Watada H
Endocr J; 2018 Jun; 65(6):657-668. PubMed ID: 29643323
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
5. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Ono Y; Kamoshima H; Nakamura A; Nomoto H
Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
[TBL] [Abstract][Full Text] [Related]
6. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
8. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
[TBL] [Abstract][Full Text] [Related]
9. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
[TBL] [Abstract][Full Text] [Related]
10. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
Okajima F; Emoto N; Kato K; Sugihara H
J Atheroscler Thromb; 2017 Feb; 24(2):157-168. PubMed ID: 27397060
[TBL] [Abstract][Full Text] [Related]
11. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Ono Y; Kameda H; Cho KY
Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
[TBL] [Abstract][Full Text] [Related]
12. Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Satoh H; Ohira T; Moriya C; Inoue I; Kuribayashi S; Seino H; Hirai H; Hiyoshi T; Watada H;
Diabetes Metab; 2017 Dec; 43(6):550-553. PubMed ID: 28947255
[No Abstract] [Full Text] [Related]
13. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
14. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Tripolt NJ; Aberer F; Riedl R; Url J; Dimsity G; Meinitzer A; Stojakovic T; Aziz F; Hödl R; Brachtl G; Strunk D; Brodmann M; Hafner F; Sourij H
Cardiovasc Diabetol; 2018 May; 17(1):71. PubMed ID: 29773079
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Koyama T; Tanaka A; Yoshida H; Oyama JI; Toyoda S; Sakuma M; Inoue T; Otsuka Y; Node K
Heart Vessels; 2018 Aug; 33(8):958-964. PubMed ID: 29427024
[TBL] [Abstract][Full Text] [Related]
16. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
Ono Y; Nakamura A; Cho KY; Nomoto H
Expert Opin Pharmacother; 2014 Feb; 15(3):311-24. PubMed ID: 24328511
[TBL] [Abstract][Full Text] [Related]
17. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
[TBL] [Abstract][Full Text] [Related]
18. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Eliasson B; Möller-Goede D; Eeg-Olofsson K; Wilson C; Cederholm J; Fleck P; Diamant M; Taskinen MR; Smith U
Diabetologia; 2012 Apr; 55(4):915-25. PubMed ID: 22237690
[TBL] [Abstract][Full Text] [Related]
19. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
[TBL] [Abstract][Full Text] [Related]
20. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
